JExpMed

@JExpMed

The Journal of Experimental Medicine publishes immunology, cancer, stem cells, microbial pathogenesis, vascular biology, neurobiology. Est. 1896 -

New York, NY
Vrijeme pridruživanja: rujan 2009.

Tweetovi

Blokirali ste korisnika/cu @JExpMed

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @JExpMed

  1. Prikvačeni tweet
    13. sij

    We are seeking a scientific editor to oversee the peer review process for submitted manuscripts and recruit high-quality submissions. PhD in immunology required. Learn more and apply:

    Poništi
  2. prije 2 sata

    Inhibiting both proline biosynthesis and lipogenesis synergistically suppresses tumor growth by Miao Liu, Binghui Li and colleagues

    Poništi
  3. prije 4 sata

    Interested in discussing your latest research with JEM editors and learning how we are making the publishing process easier for authors? Meet Scientific Editor at

    Poništi
  4. prije 4 sata

    We are pleased to present a special collection of articles to coincide with the Next Gen Immunology 2020 conference

    Poništi
  5. prije 6 sati

    Read the latest People & Ideas with Iannis Aifantis, a principal investigator at . His laboratory works on the molecular mechanisms that drive normal stem cell differentiation and malignant transformation

    Poništi
  6. prije 7 sati

    is coming out of hibernation! Look out for this week's paper pick from

    Poništi
  7. proslijedio/la je Tweet
    6. sij

    The Ogg group defines a new subset of plasmacytoid dendritic cells and its role in acute sterile skin inflammation. Published in

    Poništi
  8. proslijedio/la je Tweet
    31. sij

    Melanie Greter and colleagues summarize in this review the role of IL-34 in health and disease. Check it out! @citokinestorm

    Poništi
  9. prije 9 sati

    Our executive editor is on Twitter, follow for his insights on disease pathogenesis, publishing and his favorite poster sessions!

    Poništi
  10. prije 10 sati

    Fate mapping of resident microglia and peripheral monocytes reveals that the myeloid cells that migrate to and associate with amyloid plaques in a mouse model of Alzheimer’s disease are exclusively derived from resident microglia

    Poništi
  11. 31. sij

    Researchers reveal that DCs shape a distinct pathogen-specific CD4 T cell transcriptome & discover an unexpected role for T cell–intrinsic caspase-1 in promoting Th17 differentiation

    Poništi
  12. 31. sij

    Emerging roles of IL-34 in health and disease Iva Lelios, Melanie Greter, and colleagues

    Poništi
  13. 31. sij
    Poništi
  14. 31. sij

    Christelle Harly and Avinash Bhandoola () provide insights on a JEM study by Hosokawa et al. () establishing that transcription factor Bcl11b regulates almost completely distinct sets of genes in T cell precursors and ILC2s

    Poništi
  15. 31. sij

    The ability of T. gondii to promote a STAT3 and STAT6-dependent M2 phenotype in macrophages by injecting the virulence factor ROP16 in cis and trans subsequently limits the magnitude of the parasite-specific T cell response

    Poništi
  16. proslijedio/la je Tweet
    30. sij

    Check out our annual Best of JEM collection! Thank you, our authors, our reviewers and our readers!

    Poništi
  17. proslijedio/la je Tweet
    22. sij
    Poništi
  18. proslijedio/la je Tweet
    24. sij

    Chris Hunter and colleagues show that T. gondii ROP16 is a virulence factor able to promote M2 programs and limit the magnitude of parasite-specific T cell responses

    Poništi
  19. 30. sij

    The colonic macrophage transcription factor RBP-J orchestrates intestinal immunity against bacterial pathogens by Lan Kang, Xiaoyu Hu, and colleagues

    Poništi
  20. proslijedio/la je Tweet
    24. sij
    Poništi
  21. 30. sij

    We believe it is more important than ever for JEM to emphasize the journal’s interest in studies related to viral infection and to microbiology in general. With this intention, we welcome Sara Cherry to the JEM editorial board

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·